Novo Nordisk announced a partnership with India’s Emcure Pharmaceuticals to exclusively distribute and market its weight‑loss drug Poviztra (semaglutide injection) in the country. The agreement, announced on 10 November 2025, marks the first time Novo Nordisk will bring a semaglutide‑based obesity treatment to the Indian market under the Poviztra brand, following the launch of Wegovy in June 2025.
India’s obesity‑drug market is projected to reach roughly $2.6–3 billion by 2030, according to multiple market studies, a figure that is significantly lower than the $10 billion estimate originally cited. The country’s population exceeds 1.4 billion, providing a vast potential customer base for GLP‑1 therapies. The partnership gives Novo Nordisk access to Emcure’s established distribution network, which is expected to accelerate market penetration and help the company capture a share of the growing demand for weight‑management solutions.
While the financial terms of the exclusive distribution agreement and the pricing of Poviztra have not been disclosed, the deal is a strategic win for Novo Nordisk. It expands the company’s global footprint into a high‑growth emerging market and diversifies revenue streams beyond its current markets. The partnership also positions Novo Nordisk to benefit from India’s increasing healthcare spending and the rising demand for GLP‑1 therapies, reinforcing its leadership in metabolic health.
Novo Nordisk’s recent quarterly results illustrate a mixed performance: Q1 2025 sales grew 19% and net profit rose 28%, driven by strong demand for GLP‑1 products; Q2 2025 saw double‑digit growth, but the company lowered its 2025 guidance due to intensified competition in the U.S.; and Q3 2025 earnings fell short of expectations as Wegovy sales slowed. The Poviztra partnership is therefore a key component of Novo Nordisk’s strategy to offset headwinds in mature markets by tapping into new growth opportunities.
Eli Lilly has also entered the Indian market, launching Mounjaro and partnering with Cipla to distribute Tirzepatide. The competitive landscape underscores the importance of securing a robust distribution partner like Emcure to maintain market share and accelerate adoption of GLP‑1 therapies in India.
Overall, the partnership is expected to strengthen Novo Nordisk’s position in the Indian obesity‑drug market, enhance its distribution capabilities, and contribute to long‑term revenue growth in a rapidly expanding therapeutic area. The deal aligns with the company’s broader strategy of expanding access to its obesity treatments worldwide while navigating competitive pressures and market dynamics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.